The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Financial and time toxicity with CAR-T and bispecifics in R/R lymphoma and myeloma
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, discusses the preliminary results of a prospective cohort study examining financial toxicity and time toxicity in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) treated with CAR T-cell therapy or bispecific antibodies. The study’s mixed methods approach revealed high rates of financial and time toxicity and additionally aims to assess the impact on time spent interacting with the healthcare system and quality of life. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
